Pharmacological Evaluation and Preliminary Pharmacokinetics Studies of a New Diclofenac Prodrug without Gastric Ulceration Effect

Article, Other literature type English OPEN
dos Santos, Jean Leandro; Moreira, Vanessa; Campos, Michel Leandro; Chelucci, Rafael Consolin; Barbieri, Karina Pereira; de Castro Souto, Pollyana Cristina Maggio; Matsubara, Márcio Hideki; Teixeira, Catarina; Bosquesi, Priscila Longhin; Peccinini, Rosângela Gonçalves; Chin, Chung Man;
(2012)
  • Publisher: Multidisciplinary Digital Publishing Institute
  • Journal: International Journal of Molecular Sciences,volume 13,issue 11,pages15,305-15,320 (issn: 1422-0067, eissn: 1422-0067)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.3390/ijms131115305, pmc: PMC3509643
  • Subject: Chemistry | lactam | bioconversion, chronic inflammation | COX-inhibitor | bioconversion | QD1-999 | NSAIDs | prodrugs | Article | QH301-705.5 | anti-inflammatory | diclofenac | molecular modification | chronic inflammation | Biology (General)

Made available in DSpace on 2013-08-28T14:14:42Z (GMT). No. of bitstreams: 1 WOS000311425000095.pdf: 779292 bytes, checksum: 6c5ac5d5c6a4ed3eeede3b7bdb96ce85 (MD5) Made available in DSpace on 2013-09-30T18:06:54Z (GMT). No. of bitstreams: 2 WOS000311425000095.p... View more
  • References (48)
    48 references, page 1 of 5

    Cena, C.; Lolli, M.L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; McElroy, S.P.; Megson, I.L.; Fruttero, R.; Gasco, A. Antiinflammatory, gastrosparing and antiplatelet properties of new NO-donor esters of aspirin. J. Med. Chem. 2003, 46, 747-754.

    Autoimmun. Rev. 2011, 11, 149-153.

    3. Charakida, M.; O'Neil, F.; Masi, S.; Papageorgiou, N.; Tousoulis, D. Inflammatory disorders and atherosclerosis: New therapeutic approaches. Curr. Pharm. Des. 2011, 17, 4111-4120.

    4. Cha, Y.I.; DuBois, R.N. NSAIDs and cancer prevention: Targets downstream of COX-2. Annu. Rev. Med. 2007, 58, 239-252.

    5. Becker, R.C. Aspirin and the prevention of venous thromboembolism. N. Engl. J. Med. 2012, 366, 2028-2030.

    6. Rouzer, C.A.; Marnett, L.J. Cyclooxygenases: Structural and functional insights. J. Lipid. Res. 2009, 50, S29-S34.

    7. Go, M.F. Drug injury in the upper gastrointestinal tract: Nonsteroidal anti-inflammatory drugs. Gastrointest. Endosc. Clin. N. Am. 2006, 16, 83-97.

    8. Laine, L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120, 594-606.

    9. Silverstein, F.E.; Graham, D.Y.; Senior, J.R.; Davies, H.W.; Struthers, B.J.; Bittman, R.M.; Geis, G.S. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1995, 123, 241-249.

    10. Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 2001, 286, 954-959.

  • Metrics